Robins guided Q4 product revenue between $1.195 billion and $1.2 billion, representing 27% year-over-year growth, with a non-GAAP operating margin of 7%. Full FY26 product revenue guidance was raised ...

Q2 2026 earnings call recap: guidance cut, China/tariff headwinds, restructuring and margin plan, service growth and backlog—read now.

Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue 1 IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 2024 ...

CEO Sridhar Ramaswamy emphasized strong execution and product innovation, stating "Snowflake has delivered yet another strong quarter...our core business remains very strong. And we continue to ...

Enphase Energy Inc (ENPH) reports robust Q4 2025 results with significant product advancements, despite facing revenue declines in key markets.

Snowflake (NYSE:SNOW) reported second quarter fiscal 2026 earnings on August 27, 2025, posting product revenue of $1.09 billion, up 32% year-over-year, non-GAAP operating margin of 11%, and net ...

Teva Pharmaceuticals swung to a profit in the fourth quarter, as strong sales from its name-brand products offset underwhelming results from generics. The Israeli pharmaceutical company on Wednesday ...

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Snowflake's stock fell 10% after Q3 earnings, not due to a miss, ...

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company ...

Numbers may not sum due to rounding. Percentages calculated from unrounded figures. Hospital demand for IFC continues to increase with third quarter volumes (equivalent to FC15* therapeutic units) up ...